ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

July 17-21, 2021. Philadelphia, PA.

View by Title View by Number View Themes
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • Abstract Number: PB0925

    p.G2752S Severely Affects Dimerization of von Willebrand Factor: An Analysis of Type 3 von Willebrand Disease

    S. Okamoto1, S. Tamura1, N. Suzuki2, K. Odaira1, Y. Hayakawa1, A. Suzuki2, T. Kanematsu2, F. Hayakawa1, H. Kiyoi1, T. Kojima3, T. Matsushita2

  • Abstract Number: PB0876

    P2Y12 Receptor Antagonists and Drug-induced Thrombotic Microangiopathies: A Systematic Review of the Primary Evidence

    J.C Ho1, A. Eshaghpour1, S. Ge2, R. Foote1, M. Crowther3

  • Abstract Number: PB0427

    P2Y12 Inhibitors Administration in Intracranial Stent Procedure, the Usefulness of Monitoring

    O. Duranteau1, M. Drir1, L. Abdenour1, V. Degos1

  • Abstract Number: OC 51.2

    Paediatric D-dimer and Fibrin Degradation Products (FDP) Reference Intervals Using STA® Liatest D-Di Plus and STA® Liatest FDP

    N. Letunica1, V. Karlaftis2,1, P. Monagle3,2,1, V. Ignjatovic2,1.

  • Abstract Number: PB0912

    Palmitate Increases Gene Expression and Stimulated Secretion of von Willebrand Factor in Human Umbilical Vein Endothelial Cells

    A.K. Seliga1, K. Zabłocki1, J. Bandorowicz-Pikuła1

  • Abstract Number: PB1136

    Pancreatic-miRaCan-VTE: A R Shiny App to Aid in the Diagnosis of Pancreatic Cancer-associated VTE

    J. Oto1, A.C Larsen2, E. Plana3,1, R. Herranz1, F. Cana1, D. Hervás4, A. Cañada4, Á. Fernández-Pardo1, S.R Kristensen5,6, O. Thorlacius-Ussing2,6, P. Medina1

  • Abstract Number: PB1002

    Pandrial Platelet Reactivity in Aspirin-treated Individuals: A Comparison between Fasting and Non Fasting On-treatment Platelet Responses

    B. Nkambule1, A.D. Johnson1

  • Abstract Number: PB1010

    Pathogen-reduced Platelet Concentrates: Novel Concepts to Elucidate the Impact of Different Technologies on Platelet Function

    M. Visser1, W. Schwarz1, A. Rausch-Mueller1, S. Volpe1, A. Hilger1, U. Salge-Bartels1

  • Abstract Number: PB1152

    Pathologically Stiff Erythrocytes Can Promote Thrombosis by Impeding Contraction of Blood Clots

    V. Tutwiler1,2, R.I. Litvinov1,3, A. Protopopova1, C. Nagaswami1, C. Villa1, O. Abdulmalik4, D. Siegel1, J.E. Russell1, V. Muzykantov1, W. Lam5, D. Myers5, J.W. Weisel1

  • Abstract Number: PB0619

    Patient and Healthcare Professional Perspectives on the Use of a Personal Health Record in Hemophilia Care: A Qualitative Study

    M.R Brands1, J.J Muis2, M. Driessens3, F.JM van der Meer4, S. Meijer3, M. de Jong3, F. Bellinck4, G. Goedhart4,5, J.G van der Bom6, M.H Cnossen7, L. Haverman2, K. Fijnvandraat1,8, S.C Gouw1,6

  • Abstract Number: PB1265

    Patient Satisfaction with Quality of Care from a New Multidisciplinary Thrombosis Service

    S. Young1,2, K.O. Bonsu1, T. Lee1,2, H.V Nguyen1, R. Chitsike3,4

  • Abstract Number: PB0641

    Patient-centered Digital Health Interventions and their Effects on Health Outcomes: A Systematic Review

    M.R Brands1, S.C Gouw1,2, M. Beestrum3, M. Driessens4, R.M. Cronin5, K. Fijnvandraat1,6, S.M Badawy3,7

  • Abstract Number: PB0932

    Patient-reported Outcomes in Autosomal Inherited Bleeding Disorders: A Systematic Literature Review

    W. Al Arashi1, M.E. Houwing1, E.S. van Hoorn2, F.W. Leebeek3, J.A. Hazelzet2, S.C. Gouw4, R.E. Schutgens5, S.E. Schols6, H.F. Lingsma2, M.H. Cnossen1, The SYMPHONY consortium

  • Abstract Number: PB0584

    Patients with Hemophilia B with Inhibitors in China

    X. Dou1, X. Wang1, R. Yang1

  • Abstract Number: PB0573

    Patients with Severe Hemophilia A under Middle-dosed Prophylaxis Benefit from Multi-disciplinary Team Management, an Experience

    Z. Shiqiu1, C. Rong1, G. Hua1, L. Jia1, G. Jing1, Y. Ming2, Z. Hong2, Y. Lin2, Z. Xin3

  • Abstract Number: OC 19.2

    Patients with VEXAS Syndrome due to Somatic Mutations in UBA1 Present Commonly with Thrombosis

    E. Groarke1, B. Patel1, A. Dulau-Florea2, M. Ferrada3, J. Lotter1, I. Darden1, D. Kastner4, K. Calvo2, P. Grayson3, D. Beck4, N. Young1

  • Abstract Number: OC 69.4

    Pediatric Leukemic Lymphoblasts Produce Hemostatic System Factors: A Novel Contributor to the Hemostatic Imbalance in Pediatric Acute Lymphoblastic Leukemia

    G. Aborkhees1, K. Deitrich1, L. Mitchell1

  • Abstract Number: PB0799

    Pediatric Thromboembolism in Chiang Mai University Hospital: A 10-year Review

    P. Rahoorak1, A. Jaengkrajang1, K. Mankan1, P. Wongwai1, P. Pisanuwong1, K. Fanhchaksai1, R. Natesirinilkul1

  • Abstract Number: PB0068

    Performance Evaluation of a New VWF:GPIbM VWF Activity Assay in a Multicenter Study

    M. Kahl1, M. Boehm-Weigert1, C. Flickinger2, N. DeSimone3, D. Dietzen4, C. Eby4, K. Friedman5, K. Kottke-Marchant6, T. Ortel7, J. Patzke1, S. Pipe8, R. Sarode3, M. Merz1

  • Abstract Number: PB0071

    Performance Evaluation of the INNOVANCE Anti-Xa Assay for the Quantitative Determination of Apixaban

    M. Wilkens1, A. Doimo1, A. Wilhelm1, I. Birschmann2, E. Hod3, K. Madlener4, M. Merz1, D. Bussfeld1, U.-P. Schobel1

  • Abstract Number: PB0064

    Performance Evaluation of the INNOVANCE Anti-Xa Assay for the Quantitative Determination of Rivaroxaban

    D. Pahren1, M. Wilkens1, A. Doimo1, A. Wilhelm1, I. Birschmann2, E. Hod3, K. Madlener4, M. Merz1, D. Bussfeld1, U.-P. Schobel1

  • Abstract Number: OC 08.3

    Peri-operative PK-guided Dosing of Desmopressin Combined with FVIII Concentrates in Hemophilia A: Final Results of the DAVID Study

    L.G.R. Romano1, L.M. Schütte1, R.M. van Hest2, K. Meijer3, B.A.P. Laros - van Gorkom4, L. Nieuwenhuizen5, J. Eikenboom6, F.C.J.I. Heubel-Moenen7, N. Uitslager8, M. Coppens9, K. Fijnvandraat10,11, M.H.E. Driessens12, S. Polinder13, M.H. Cnossen14, F.W.G. Leebeek1, R.A.A. Mathôt2, M.J.H.A. Kruip1, On behalf of the SYMPHONY Consortium

  • Abstract Number: OC 46.1

    Peri-procedural Heparin Use in Patients Receiving Edoxaban: Analyses of the Noninterventional Global EMIT (Edoxaban Management in Diagnostic and Therapeutic Procedures) Study

    A. Santamaria1, C. Chen2, C. Von Heymann3, T. Vanassche4, M. Saxena5, J. Jin2, M. Unverdorben2, P. Colonna6

  • Abstract Number: PB0109

    Peridontal Injury Prompts Remote Spleen Activation and the Generation of Spleen Procoagulant Microvesicles in a Periodontitis Murine Model

    H. EL Itawi1, S. Amissi1, F. Batool2, C. Stutz1, F. El Ghazouani1, A.B. Chaker1, A.W. Qureshi1, F. Moschovaki-Filippidou1, C. Auger1, E. Anglès-Cano3, O. Huck2, F. Toti4

  • Abstract Number: PB1310

    Perinatal Outcome of Normal Pregnant and Pregnant Women Hospitalized for Hypertension (PIH: Pregnancy Induced Hypertension) and Studied for Antiphospholipid Antibodies (aPL) at Time of PIH Onset

    B. Grand1, L.S. Voto1

  • Abstract Number: PB0941

    Perioperative Management of Patients with von Willebrand Disease Undergoing Surgical Interventions

    R. Toenges1, L. Haack2, B. Krammer-Steiner2

  • Abstract Number: LPB0003

    Persistence Pattern to Oral Anticoagulants among Non-valvular Atrial Fibrillation Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants: A Cohort Study

    M.M. Toorop1, Q. Chen1, M.J. Kruip2,3, F.J. van der Meer1, M. Nierman4, L. Faber5, L. Goede6, S.C. Cannegieter1, W.M. Lijfering1

  • Abstract Number: PB0089

    Persistently Low Levels of Antithrombin in Trauma Patients Associated with Disseminated Intravascular Coagulation

    S. Gando1,2, T. Wada2

  • Abstract Number: OC 23.1

    Personalized Cancer-associated Thrombosis Risk Assessment: Integration of Plasma Proteomics, Clinical Characteristics, and Machine Learning

    J. Zwicker1, E. Elango1, R. Patell1, M. Marchetti2, L. Russo2, C. Verzeroli2, C. Giaccherini2, S. Gamba2, R. Flaumenhaft1, C.J Tartari2, I. Vlachos1, A. Falanga2,3

  • Abstract Number: PB0859

    PF4/Polyanion ELISA-negative Antibodies to PF4 and Non-PF4 Targets Can Mediate Platelet Activation and Cause Heparin-induced Thrombocytopenia (HIT)

    B. Singh1, C. Jones2, D.A. Garcia3, N. Leung1, R.S. Go1, R. Leger1, N. Heikal1, R. Pruthi1, D. Chen1, A. Padmanabhan1

  • Abstract Number: OC 17.4

    Pharmacodynamics of Bolus with and without Infusion of Cangrelor in Healthy Volunteers: A Dose-finding, Open-label, Pilot Trial

    G. Gelbenegger1, J. Grafeneder2, G.M. Gager3, J.M. Siller-Matula3, M. Schwameis2, B. Jilma1, C. Schörgenhofer1

  • Abstract Number: OC 24.3

    Pharmacokinetic Analysis of fVIII Exposure Identifies an Immunogenicity Threshold after AAV-FVIII Gene Therapy in a Murine Hemophilia A Model

    T.S. Lundgren1, H.T. Spencer1,2, C.B. Doering1,2

  • Abstract Number: PB0568

    Pharmacokinetic-guided Prophylaxis Improved Clinical Outcomes in 46 Pediatric Patients with Severe Hemophilia A

    H. Kun1, L. Gang1, Z. Yingzi1, W. Xinyi1, C. Zhenping1, W. Runhui1

  • Abstract Number: PB0077

    Pharmacokinetics and Pharmacodynamics of Abelacimab (MAA868), a Novel Dual Inhibitor of Factor XI and Factor XIa

    B.A. Yi1, D. Freedholm1, N. Widener1, X. Wang2, E. Simard2, L. Galitz3, N.M. Al-Saady4, N.E. Lepor5, M. Lovern2, D. Bloomfield1

  • Abstract Number: PB0614

    Pharmacokinetics-adjusted Dosing of Rurioctocog Alfa Pegol (Adynovi) in Adult Patients with Haemophilia A

    J. Treliński1, K. Chojnowski1, M. Robak1, A. Mital2, E. Zarzycka2, M. Bober3, J. Dziamska3, T. Woźny3, D. Urbaniak-Kujda4, I. Prajs4, M. Podolak-Dawidziak4

  • Abstract Number: PB0917

    Pharmacokinetics/Pharmacodynamics (PK/PD) of Recombinant von Willebrand Factor (Vonicog Alfa) in Adult Patients with von Willebrand Disease (VWD) during Prophylactic Treatment

    A. Iorio1, F. Leebeek2, S. Susen3, A. Shapiro4, G. Özen5, B. Mellgård5, Y. Wang6

  • Abstract Number: PB1224

    Pharmacologic Profiles of Direct Oral Anticoagulants in Patients Receiving Rituximab-CHOP Chemotherapy

    T. Punnachet1, T. R. Cressey1, P. Apiwatnakorn2, A. Koonarat3, L. Norasetthada1, A. Tantiworawit1, E. Rattaritamrong1, T. Rattanathammethee1, S. Huntrakool1, P. Piriyakhuntorn1, C. Chai-Adisaksopha1

  • Abstract Number: PB0958

    Pharmacological Characterization of eNOS-based Megakaryocyte Subpopulations and its Implications for their Platelet Progeny

    A. Asgari1, P. Jurasz1,2

  • Abstract Number: OC 71.1

    Pharmacological Targeting of Coagulation Factor XI Mitigates the Development of Experimental Atherosclerosis in Low-density Lipoprotein Receptor-deficient Mice

    A. Ngo1, K. Jordan1, P. Mueller1, M. Hagen1, S. Reitsma1, C. Puy1, A. Revenko2, C. Lorentz1, E. Tucker1, Q. Cheng3, M. Hinds1, S. Fazio1, B. Monia2, D. Gailani3, A. Gruber1, H. Tavori1, O. McCarty1

  • Abstract Number: PO174

    Pharmacological Venous Thromboembolism Prophylaxis in an Internal Medicine Ward: Cross-sectional Observational Study

    G. Durao-Carvalho1, A. Canoso1, J. Louro1, R. Amorim1

  • Abstract Number: LPB0128

    Phase 3 Trial Results: Prophylaxis with Recombinant von Willebrand Factor in Patients with Severe von Willebrand Disease

    F.WG Leebeek1, F. Peyvandi2, M. Escobar3, A. Tiede4, G. Castaman5, J. Gu6, B. Mellgård7, B. Ewenstein7, G. Özen7

  • Abstract Number: OC 72.2

    Phase I/II Ongoing Study of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Immune Thrombocytopenia: Extended Follow-up and Long-term Analyses with Optimal Dose

    D.J. Kuter1, N. Tzvetkov2, M. Efraim3, Z. Kaplan4, J. Mayer5, P. Choi6, A.J.G. Jansen7, V. McDonald8, R. Baker9, R. Bird10, M. Garg11, J. Gumulec12, M. Kostal13, T. Gernsheimer14, W. Ghanima15, O. Bandman16, P. Arora16, Q. Tran16, H. Guo17, N. Cooper18

  • Abstract Number: OC 67.2

    Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression After AAV Gene Transfer for Hemophilia A

    L.A. George1,2, P.E. Monahan3, M.E. Eyster4, S.K. Sullivan5, M.V. Ragni6, S.E. Croteau7,8, J. Rasko9,10, M. Recht11, B.J. Samelson-Jones1,12, A. MacDougall13, K. Jaworski13, R. Noble13, M. Curran3, K. Kuranda13, F. Mingozzi13, K.Z. Reape3, X.M. Anguela3, K.A. High3

  • Abstract Number: PB0700

    Phenotype-Genotype Relationship in Patients with Hereditary FXI Deficiency

    C. Albayrak1, D. Albayrak2, H. Gürkan3, S. Demir3

  • Abstract Number: PB0761

    Phenotypic Changes in Platelets during Measles Virus Infection of Rhesus Macaques (Macaca Mulatta)

    S. Guerrero-Martin1,2, E. Shirk1, J. Brockhurst1,3, N. Peart Akindele1,3, J. Villano1, D. Griffin1,3, K. Metcalf Pate2,1

  • Abstract Number: PB0023

    Photodynamic Therapy with 5- Aminolevulinic Acid and B-mode Ultrasound-guided Catheter-based Low-level Red Laser Results in Cerebrovascular Neointimal Hyperplasia Regression

    H. Mehrad1,2, A. Sultan- Qurraie3

  • Abstract Number: PB0187

    Physicians’ Knowledge and Management Practices of COVID-19 Coagulopathies in Pregnancy

    S. Jevtic1, A.K. Malinowski2,3, M. Othman4,5, R. Abdul Kadir6

  • Abstract Number: PB0987

    PI4P and PI(4,5)P2 Immunofluorescence Staining Optimization in Human Platelets

    A. Bura1, I. Đurić1, S. Čabrijan1, A. Jurak Begonja1

  • Abstract Number: OC 09.1

    Piggyback Knockdown Screen of Glycosyltransferases in Zebrafish: Identification of Novel Regulators of von Willebrand Factor Levels

    N. Iyer1, A. Al Qaryoute1, P. Jagadeeswaran1

  • Abstract Number: PB0851

    PK/PD Modeling and Simulations Highlight the Importance of the Intravenous Loading Dose and Daily Dosing Regimen with Caplacizumab for Patients with aTTP

    T. Sou1, F. Callewaert2, R. de Passos Sousa3, M.L. Sargentini-Maier1

  • Abstract Number: PB0840

    Plasma BioID of ADAMTS13

    H. Madarati1, K. Singh1, T. Sparring1, C. Kretz1

  • Abstract Number: PB1090

    Plasma Biomarkers for Predicting Risk of Venous Thromboembolism (VTE) in Ambulatory Cancer Patients Receiving Chemotherapy

    D. Roy1, T.F. Wang2,3, M. Carrier2,3, E. Mollanji2,3, P. Liu4, P. Wells2,3

  • Abstract Number: PB0733

    Plasma D-dimer and Fibrinogen Levels Correlates with Tumour Size and Disease Progression in Nigerian Breast Cancer Patients

    O. Izuegbuna1, O. Agodirin2, H. Olawumi2, S. Olatoke2

  • Abstract Number: PB0939

    Plasma-derived VWF/FVIII Concentrate (wilate®) for Haemostasis in Women with VWD during Childbirth

    A. Iorio1, A. Srivastava2, P. James3, A. Ma4

  • Abstract Number: PB0347

    Plasmatic Rivaroxaban Concentration Estimation through the Measurement of Anti Xa Activity Calibrated with Heparin Calibrators Using 3 Reactive/Instrument Systems: Multicenter Study

    M. Martinuzzo1,2, C. Duboscq3, M. Arias4, M.S. López1,2, E.S Viñuales5,2, D. Mezzarobba5, V. Privitera5, D. Penchasky5, F. Chuliber5, J. Ceresetto3, M. Gurfinkiel4, L. Barrera1,2

  • Abstract Number: OC 26.4

    Plasmin-responsive Procoagulant Synthetic Platelets for Fibrin Clot Stabilization in Hemorrhage Control

    A. Sen Gupta1, U. Didar Singh Sekhon1, N. Luc1, A. Girish1, M. de la Fuente1, M. Nieman1

  • Abstract Number: OC 41.3

    Plasminogen, but Not Fibrinogen, Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth and Metastasis

    Y. Yang1, S. Abrahams1, K. Davey1, A. Revenko2, M. Fishel3, A. Wolberg1, M. Flick1

  • Abstract Number: PB1061

    Plasmocytoid Dendritic Cells Activity in Asymptomatic Antiphospholipid Carriers and in Primary and Secondary Antiphospholipid Syndrome with Thrombosis

    A.P. Rosa dos Santos1, B. Cardoso Jacintho2, C. de Oliveira Vaz2, G. Lisiane Tripiquia Vechiatto Mesquita1, J.D. Oliveira2, J. Annichino-Bizzacchi3, S. Appenzeller4, B. Moraes Mazetto5, F. A. Orsi6

  • Abstract Number: PB0822

    Platelet Activation and Function in Adult Patients with Primary Immune Thrombocytopenia

    J. Machacek1, L. Buresch1, D. Mehic1, T. Schramm1, M. Fillitz2, B. Dixer2, T. Flasch1, T. Anderle1, A. Rath1, C. Ay1, I. Pabinger1, J. Gebhart1

  • Abstract Number: LPB0141

    Platelet Activation and Platelet Indices as Markers for Disease Progression in Women with Breast Cancer

    Y. Tera1,2, H. Azzam1, N. Abousamra1, M. Zaki3, A. Eltantawy4, M. Awad4, H. Ghoneim1, M. Othman2

  • Abstract Number: OC 70.4

    Platelet Activation via PI3K/AKT Signaling Pathway in COVID-19

    L. Pelzl1, A. Singh1, J. Funk1, A. Witzemann1, J. Zlamal1, I. Marini1, K. Weich1,2, W. Abou-Khalel2, S. Hammer2, G. Uzun2, K. Althaus1,2, T. Bakchoul1,2

  • Abstract Number: PB0978

    Platelet Activity and Platelet-induced Endothelial Inflammatory Pathways in Treated HIV Is Lowered by Clopidogrel: A Randomized Control Trial

    T. Schwartz1, E. Maracantoni1, N. Allen1, M. Cambria1, R. Dann1, M. Garshick1, J.S. Berger1

  • Abstract Number: PB1060

    Platelet Activity from Antiphospholipid Syndrome (APS) Patients is Enhanced: Possible Role of the ADP Signaling Pathway

    G. Leonardi1, C.H. Lescano1, A.P.R. Dos Santos2, B.C. Jacinto2, B.M. Mazetto2, F.A. Orsi3,4, F.Z. Mónica1

  • Abstract Number: PB0817

    Platelet Apoptosis and Autophagy in Pediatric Immune Thrombocytopenia: New Mechanistic Insights

    T. Stein1, R. Hinselmann1, C. Gowin1, D. Greber1, S. Shllaku1, N. Gölz1, M. Schmugge1, F.D. Franzoso1

  • Abstract Number: OC 11.2

    Platelet Binding to Polymerizing Fibrin is Avidity-driven and Requires Activated αIIbβ3

    C.L. Buitrago1, O. Bentur1, B. Coller1

  • Abstract Number: OC 52.3

    Platelet Chemokines and Integrins Antagonistically Steer Neutrophil Activation in Arterial Thrombus Formation

    C. Schönichen1,2, M. Nagy1, S.LN Brouns1, S. Montague3, F. Ní Ainle4, K. Knoops5, R.R Koenen1, O. Soehnlein6, S.P Watson7, J.WM Heemskerk1

  • Abstract Number: PB0208

    Platelet Dynamics in Hospitalized Patients with SARS CoV-2 Infection

    V.E. Delgado Pinos1, R.M. Martín Rojas1, C. Pascual Izquierdo1,2, J.L. Díez Martín1,2,3, G. Perez Rus1,3

  • Abstract Number: PB0892

    Platelet Dysfunction in Noonan Syndrome

    S. Sorrentino1, I. Lazzareschi2,3, M. Capurso2, R. Onesimo2, C. Leone2, A. Romano2, M. Mele2, G. Zampino2,3, E. De Candia1

  • Abstract Number: OC 15.1

    Platelet Factor 4 (PF4) Enhances in vitro Neutrophil Extracellular Traps (NET) Capture of Coronaviruses: Clinical and Therapeutic Implications

    M. Ishizuka1, B. Estevez1, A. Sarkar1,1, M.A. kowalska1, L. Rauova1, M. Poncz1, K. Gollomp1

  • Abstract Number: OC 40.3

    Platelet Fibrinogen Receptor Expression and Platelet Function Decreases as Duration of ECMO Increases in Paediatric Veno-arterial ECMO Patients

    S. Van Den Helm1, H.P. Yaw1, N. Letunica1, R. Barton1,2,3, F. Newall1,2,3, S. Horton2,3, G. MacLaren1,2,3,4, R. Chiletti1,2, A. Johansen1,2, D. Best1,2, J. McKittrick2, W. Butt1,2,3, Y. d'Udekem1,3,5, M. Linden6, P. Monagle1,2,3, V. Ignjatovic1,3

  • Abstract Number: LPB0073

    Platelet Function Is Inhibited by Dengue Virus

    MA. Mosso-Pani1, M.I. Salazar2, N. Corona-de-la-Peña3

  • Abstract Number: PO160

    Platelet Hyperaggregability and Migraine Headache – A Single Centre Experience

    M. Brunclikova1, L. Stanciakova1, J. Ivankova1, M. Skerenova2, T. Simurda1, M. Dobrotova1, P. Holly1, I. Skornova1, P. Kubisz1, J. Stasko1

  • Abstract Number: PB0764

    Platelet Involvement and its Association with Mortality in COVID-19 Patients at a Safety-net Hospital

    L.F. Gonzalez-Mosquera1, S. Gomez-Paz1, E. Lam1, D. Cardenas-Maldonado1, J. Fogel2, V. Adi1, S. Rubinstein1

  • Abstract Number: PB1048

    Platelet microRNA Release in the Context of Agonist-stimulation and Thrombosis

    T.L. Krammer1, S. Zeibig2, H.-P. Holthoff2, M. Hackl1

  • Abstract Number: OC 41.1

    Platelet microRNAs Inhibit Primary Tumor Growth via Broad Modulation of Tumor Cell mRNA Expression in Ectopic Pancreatic Cancer in Mice

    J.G. Wurtzel1, S. Lazar1, I. Astsaturov2, A.S. Weyrich3, J.W. Rowley3, L. Goldfinger1

  • Abstract Number: OC 10.3

    Platelet Proteome and Variability in the Responsiveness to Low-dose Aspirin in Patients with Cardiovascular Disease

    S. Ciotti1,2, P.G. Simeone1,2, R. Liani1,2, R. Tripaldi1,2, A. Boccatonda3,2, D. D'Ardes3,2, A. Recchiuti4, M. Romano4, F. Santilli1,2,3

  • Abstract Number: OC 35.1

    Platelet TFPIα Dampens Prothrombotic and Fibrotic Responses to Radiation Injury in Mouse Heart

    S. Maroney1, N. Martinez1, J. Peterson1, J. Lincoln2, A. Mast1

  • Abstract Number: LPB0074

    Platelet Transfusion Does Not Prevent Experimental Polymicrobial-induced Septic Shock in Mice

    Y. Rabouel1, S. Magnenat1, F. Lefebvre1, X. Delabranche2, C. Gachet1, B. Hechler1

  • Abstract Number: PB0011

    Platelet-derived Let-7e is an Independent Predictor of Long-term All-cause Mortality in Patients with Type 2 Diabetes Mellitus

    C. Eyileten1, J. Pordzik1, D. Jakubik1, P. Czajka1, M. Wolska1, J. Jarosz-Popek1,2, A. Fitas1, A. Nowak1, S. De Rosa3, A. Gąsecka4, A. Kapłon-Cieślicka4, J.M. Siller-Matula5, M. Postuła1

  • Abstract Number: PB0021

    Platelet-derived microRNAs Are Increased after Transcatheter Aortic Valve Implantation and May Predict Adverse Outcomes in Patients with Heart Failure

    C. Eyileten1, A. Fitas1, J. Jarosz-Popek1,2, T. Adem1, D. Jakubik1, M. Wolska1, A. Nowak1, P. Czajka1, M. Postuła1, A. Gąsecka3

  • Abstract Number: LPB0135

    Platelet-rich Neutrophil-platelet Micro-emboli Contribute to Cigarette Smoke-induced Influenza Severity

    T.W. Kaminski1, T. Brzoska1, X. Li1, R. Vats1, R. Dubey1, K. Nickolich1, K. Robinson1, T. Nyunoya1, P. Sundd1

  • Abstract Number: LPB0129

    Platelet-specific Deletion of Acetyl-CoA Carboxylase 1 Decreases Phospholipid Content and Impairs Platelet Functions

    M. Octave1, L. Pirotton1, A. Ginion1, V. Robaux1, S. Lepropre1, S. Kautbally1, Y. Senis2, Z. nagy3, J. Ambroise4, B. Guigas5, M. Giera5, L. Bertrand1, C. Beauloye1, S. Horman1

  • Abstract Number: PB0253

    Platelets and Neutrophil Extracellular Traps (NETs) in Immunothrombosis Progression at COVID-19

    I. Vasilenko1,2, A. Gur’ev1, D. Kassina1, V. Metelin3,2, V. Schelkova1

  • Abstract Number: PB0319

    Platelets Collected from Blood Diversion Pouches Are an Appropriate Alternative for Functional and Bioenergetic Analyses

    O. Esparza1, G. Hernandez1, M. Kelher1, K. Kelly2, C. Silliman1, L. Dumont2, P. Davizon-Castillo1

  • Abstract Number: PB0201

    Platelets from Donors of Convalescent Plasma after Mild COVID-19 Do Not Express Procoagulant Phenotype

    G. Uzun1, L. Pelzl2, W. Abou-Khalel2, A. Singh2, S. Nowak-Harnau1, K. Althaus1,2, T. Bakchoul1,2

  • Abstract Number: OC 31.3

    Platelets from Patients with MYH9 Related Disorders Are Mechanically Stiffer

    L. Sachs1, J. Baumann2, J. Wesche1, P. Nestler3, C. Zaninetti1, A. Greinacher1, M. Bender2, O. Otto3, R. Palankar1

  • Abstract Number: PB0155

    Platelets of COVID-19 Patients Are Refractory due to Thrombin Receptor Desensitizing in the Bloodstream

    A. Martyanov1,2,3, A.E. Boldova2, M.G. Stepanyan4,2, O.I. An5,2, S.V. Tsarenko6, S.A. Rumyantsev7, S.S. Karamzin2, M.A. Panteleev2,1,4, A.G. Rumyantsev1, F.I. Ataullakhanov2,1,4, A.N. Sveshnikova4,1,2,5

  • Abstract Number: OC 74.4

    Platelets Preferentially Bind Senescent Red Blood Cells and Regulate in their Clearance

    B. McMorran1, D. Ningtyas1, F. Leitner2, M. Sawbridge1, J. Lee3, M. Rug3

  • Abstract Number: PB0747

    Platelets Promoted Malignancy Involving Exosomal HMGB1

    J.-D. Wang1, C.-J. Chen1, S.-L. Liao1, S.-W. Huang2

  • Abstract Number: PB0759

    Platelets Show a Distinct Response in a Controlled Human Malaria Infection (CHMI) Model

    A. Singh1, A. Witzemann1, L. Pelzl1, I. Marini1, F. Rigoni1, J. Zlamal1, A. Kreidenweiss2, B. Mordmüller2, P. Kremsner2, T. Bakchoul1,3

  • Abstract Number: OC 58.4

    Platelets Stimulate Programmed Death-ligand 1 Expression by Cancer Cells: Inhibition by Anti-platelet Drugs

    A. Asgari1, G. Lesyk1, E. Poitras2, N. Govindasamy3, K. Terry2, R. To1, V. Back1, J. Rudzinski3, J. Lewis3, P. Jurasz1,2

  • Abstract Number: OC 61.1

    Pleiotropic Role of miR-146a in Driving Metabolism Reprogramming Causes Platelet Hyperreactivity and Thrombosis

    S. Águila1, A.B Arroyo1, J.C Cañaveras-García2, M.P Fernández-Pérez1, A.M De los Reyes-García1, N. García-Barberá1, L. Reguilón-Gallego1, L. Zapata-Martínez1, I. Ruiz-Lorente1, V. Vicente3, J. Rivera3, A. Lahoz2, M.P. Gratacap4, R. González-Conejero1, C. Martínez1

  • Abstract Number: OC 01.2

    Podocyte Tissue Factor Suppresses Spontaneous Sterile Renal Inflammation

    J. Manoharan1, R. Rana1, D. Gupta1, A. Elwakiel1, K. Shahzad1, B. Isermann1

  • Abstract Number: OC 30.1

    Podoplanin and Tissue Factor Cooperate in Triggering Microthrombosis in Experimental Glioblastoma and Are Released to Systemic Circulation as Cargo of Extracellular Vesicles

    N. Tawil1,2, R. Bassawon1, B. Meehan2, L. Montermini2, A. Nehme1, D. Choi1,2, L. Adnani1,2, C. Spinelli1,2, N. Mackman3, Y. Riazalhosseini1, H. Najafabadi1, J. Rak1,2

  • Abstract Number: PB0042

    Polycationic Molecules Towards the Inhibition of Procoagulant and Antifibrinolytic Properties of Nucleic Acids

    S. Vappala1,2,3, M.T. Kalathottukaren1,2,3, C. La1,2,4, S. Abbina1,2,3, L. Abraham1,5, I. Constantinescu1,2,3, E. M. Conway1,2,6, C. A Haynes1,2,7, J. N. Kizhakkedathu1,2,3,8

  • Abstract Number: PB1038

    Ponatinib Induces Vasculitis with Immune Cells Expressing Coagulation Factors FV & FVIII

    P. Zeng1, A. Merkulova1, E. Chan1, A.H. Schmaier1

  • Abstract Number: PB0976

    Ponatinib Inhibits Collagen Induced Platelet Aggregation and Coated-platelet Formation in Human Platelets

    I. Beke Debreceni1, G. Mezei2, P. Batár2, L. Kozma3, J. Kappelmayer1

  • Abstract Number: PB0692

    Population Parmacokinetics of rFXIII (Catridecacog) and Clinical Outcomes of Prophylaxis in an Italian Population of Patients with Factor XIII Deficiency

    E. Zanon1, S. Pasca1, G. Sottilotta2, A.C. Molinari3, L. Banov3, A. Ferretti4, P. Di Gregorio5, B. Pollio6, S.M. Siboni7, R. Palla7, F. Peyvandi7, M. Pizzuti8, L.D. Notarangelo9, P. Cojutti10, C. Biasoli11, P. Simioni1, F. Pea10

  • Abstract Number: PB0580

    Population Pharmacokinetic Modeling of Factor Concentrates in Hemophilia: A Detailed, Clinical Overview and Evaluation of Best Practice

    M.H. Goedhart1, L.H. Bukkems2, C.M. Zwaan1, R.A. Mathot2, M.H. Cnossen1, for the OPTI-CLOT study group and SYMPHONY consortium.

  • Abstract Number: LPB0059

    Population Pharmacokinetics of Anti-Xa Levels in COVID-19 ICU Patients Receiving Prophylaxis for Thrombo-embolic Events Using Nadroparin

    L.G.R. Romano1, H. Endeman2, N.G.M. Hunfeld2,3, T. Preijers3

  • Abstract Number: OC 20.4

    Portal Vein Thrombosis(PVT) in Neonates and Children: A Ten-year Prospective Registry of a Tertiary Care Single-centre in Argentina

    C. Cervio1, M. Hepner1, B. Bianco1, G. Pieroni1, E. Annetta1, J.P. Frontroth1, G. Sciuccati1

  • Abstract Number: PB0185

    Post Hospital Discharge Thrombosis in Patients with COVID-19

    P. Li1, S. Kaatz2, W. Zhao3, K. Latack1, L. Schultz1, L. Poisson1

  • Abstract Number: PB0527

    Postoperative Bleeding Complications in Patients with Hemophilia Undergoing Major Orthopedic Surgery: A Prospective, Multicenter Observational Study

    T.W. Buckner1, B. Kleiboer2, M. Layer2, L. Cafuir3, A. Cuker4, M. Escobar5, M.E. Eyster6, E. Kraut7, A.D. Leavitt8, S.R. Lentz9, D. Quon10, M. Ragni11, D. Thornhill1, M. Wang1, N.S. Key2

  • Abstract Number: OC 62.4

    Postpartum Hemorrhage in Women with von Willebrand Disease and Carriers of Hemophilia: A Retrospective Analysis

    M.C. Punt1, F. van Leusden1, K.W.M. Bloemenkamp2, M. Coppens3, M.H.E. Driessens4, S. Haitjema5, F.C. Heubel-Moenen6,7, A.T. Lely2, A.B. Mäkelburg8, L. Nieuwenhuizen6,9, W.W. van Solinge5, J.L. Saes10,6, S.E.M. Schols10,6, R.E.G. Schutgens1, J. Eikenboom11, M.J. Kruip12, K.P.M. van Galen1

  • Abstract Number: PB0587

    Posttraumatic Stress Disorder and Posttraumatic Stress Symptoms Among Adults with Hemophilia A and B

    A. Stahl1, K. Barnett2, A. Wilson3, H.S. Park1, M. Geary1, S. Ren4, D. Neuberg4, A. Parnes1

  • Abstract Number: PB0251

    Potential Markers to Predict Mortality in COVID-19

    C. Klapheke1, H. McRae1, T. Love1, M. Refaai1

  • Abstract Number: LPB0021

    Practical Application of FIX-Padua Field Study Results Enables a Comparison of FIX:C Results Across AAV Gene Therapy Trials Independent of FIX:C Assay Reported

    E. Shehu1, J.H. Foley1, E. Gray2, A. Riddell3,4, A. Goodale1, I-M. Yu1, J. Little1, D. Shattock1, S. Kitchen5, P. Chowdary3,4, A. Nathwani3,4, R. Corbau1

  • Abstract Number: PB1281

    Practical Considerations for Treatment of Left Ventricular Thrombus with Direct-acting Oral Anticoagulants

    R. Brazilek1, H. Bortz1, C. Corallo1, J. McFadyen1

  • Abstract Number: LPB0056

    Pre-admission Anticoagulant Therapy and Mortality in Hospitalized COVID-19 Patients: A Covid Predict Retrospective Cohort Study

    T.F. van Haaps1, D. Collard1, S. Middeldorp1, M. Coppens1, M.D. de Kruif2, H. ten Cate3, P.R. Tuinman4, R.A. Douma5, M.C. Muller6, A.C. Reidinga7, M.A. Heuvelmans8, M. Oudkerk8, F.H. van Osch9, J.P. van den Bergh9, A. Maas9, N. Gritters10, M. Ten Wolde5, N.P. Juffermans11, N. van Es1, on behalf of the Dutch COVID & Thrombosis Coalition

  • Abstract Number: PB0559

    Predicted FVIII Consumption of BAY 94-9027 Compared with Standard- and Extended-half-Life FVIII Products in Patients with Severe Hemophilia A

    A. Solms1, A. Shah2, E. Berntorp3, A. Tiede4, A. Iorio5, A. Bröker6, M.E. Mancuso7

  • Abstract Number: PB0470

    Predicting the Duration of Recombinant Factor VIIa Effect on Tail Bleeding by the Thrombin Generation Assay in Hemophilia A Mice

    S. Surov1,2, M. Ovanesov1

  • Abstract Number: OC 57.3

    Prediction of Mortality in Patients with Recently Diagnosed Venous Thromboembolism: The GARFIELD-VTE Mortality Risk Model

    A.E. Farjat1, K.A. Fox2, A.G. Turpie3, S.Z. Goldhaber4, H. Bounameaux5, P. Prandoni6, J.I. Weitz7, F. Dalgaard8, P. Angchaisuksiri9, S. Haas10, S. Schellong11, W. Ageno12, S. Goto13, E. Panchenko14, C.-E. Chiang15, C. Jerjes Sanchez Diaz16, J. Muntaner17, P. Verhamme18, E. Tse19, A.K. Kakkar1,20

  • Abstract Number: PB1125

    Prediction of Venous Thromboembolism among Ambulatory Cancer Patients with Gastrointestinal Malignancies – A Retrospective Analysis

    K. Pavithran1, H. Jayamohanan1, S. Soman1

  • Abstract Number: PB1186

    Predictors for Prognosis in Patients with Nonfatal Pulmonary Embolism in COVID-19 Pandemic

    N. Diaconu1, T. Cuzor1, D. Lupu1, A. Grosu1, L. Caldare1

  • Abstract Number: OC 44.2

    Predictors of Lupus Anticoagulant Test Variability over Time and its Associations with Future Thrombotic Events: Results from the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)

    M. Colling1,2, F. Posch1,3, S. Koder1, C. Ay1, I. Pabinger1, J. Gebhart1

  • Abstract Number: PB1277

    Predictors of Recurrence of Venous Thromboembolic Disease after Suspension of Anticoagulation

    M.L. Posadas-Martinez1, F. Torres Gómez1, C. Juana2, M.F. Grande Ratti1, M. Burgos1, D. Mezzarobba1, N. Schutz1, J. Ruberto1, M.F. Dovasio1, M. Martinuzzo1, F. Gonzalez Bernaldo De Quiros1, F.J. Vazquez1, D.H. Giunta1

  • Abstract Number: LPB0091

    Predictors of the Development of the Post-thrombotic Syndrome: A Sub-analysis of the ATTRACT Trial

    F. Rinfret1,2, C.-S. Gu3, S. Vedantham4, S. Kahn2,1

  • Abstract Number: PB1300

    Preeclampsia and Inflammatory Lipid Mediators: A Longitudinal Study

    L. Perucci1, K. Pinto1, S. Silva1, E. Lage2, P. Teixeira2, A. Barbosa2, P. Alpoim2, L. Sousa2, L. Dusse2, A. Talvani1

  • Abstract Number: PB0658

    Preferences of People with Hemophilia A and B for Treatments Including Gene Therapies in the US: A Discrete Choice Experiment

    M. Witkop1, G. Morgan2, J. O'Hara2,3, M. Recht4,5, T.W. Buckner6, D. Nugent7, R. Curtis8, B. O’Mahony9,10, M.W. Skinner11,12, B. Mulhern13, M. Cawson2, T. Ali14, E. Sawyer14, N.(. Li14

  • Abstract Number: PB1298

    Pregnancy and Heparin: Peripartum Management. Experience of Two Centers in Argentina

    S. Molnar1, C. Gumpel2

  • Abstract Number: OC 34.4

    Pregnancy from in vitro Fertilization is Associated with Increase in Risk of Venous Thromboembolism when Compared to Normal Pregnancy: A Systematic Review and Meta-analysis

    R. Dewangga1, K. Winston2

  • Abstract Number: PB0805

    Preliminary Results of the Adventh-pediatric Registry in a Southeastern Brazilian City

    T. Mello1, S. Rigatto1, R. Vilela1, M. Veríssimo2, T. Rodrigues1, G. Nunes1, S. Huber1, V. Pinheiro1, J. Pires2, S. Montalvão1, J. Annichino-Bizzacchi1

  • Abstract Number: PB1194

    Premature Mortality Burden Related to Pulmonary Embolism in Cuba

    K. Valdés-Díaz1, H. Hernández-Negrín1

  • Abstract Number: OC 75.1

    Prenatal Therapy with Placental Cells Transduced with an Engineered fVIII Transgene Results in Curative fVIII Plasma Levels for 3 Years after Birth, Without Immune- or Toxicity-related Adverse Events

    M. Rodriguez1, B. Trevisan1, s. george1, R. Ramamurthy1, J. Shields2, D. Schwahn3, J. Figueroa4, D. Meares4, J. Owen4, M. Gautreaux4, A. Atala1, C. Doering2, HT. Spencer2, C. Porada1, G. Almeida-Porada1

  • Abstract Number: PB0096

    Preoperative Hemorrhagic Risk Assessment: Knowledge, Attitude and Practice among Surgeons and Anesthesiologists

    E. Hammami1, M. Cheikhrouhou1, M.Y. Kaabar1, S. Guermazi1

  • Abstract Number: LPB0107

    Preoperative Measurement of Platelet Contribution to Clot Stiffness (PCS) with the Quantra® QPlus® System and Bleeding after Cardiac Surgery

    T.B Washburn Jr1, W. Houdijk2, R. Sudhagoni2

  • Abstract Number: PB1086

    Prescribing Patterns, Efficacy and Safety of Direct Oral Anticoagulants (DOAC) Usage in a Tertiary Hospital

    K.Y. Yong1, S. Leow2, E.S. Yap1, P.S. Ong2, S.C. Tan1, P.W. Goh1

  • Abstract Number: OC 65.4

    Prescription Patterns and Impact of Anticoagulant Therapy in Patients with Atrial Fibrillation who Had Active Cancer

    C. Chai-Adisaksopha1, A. Watanabe2, P. Dilokthornsakul3, L. Navaravong2, N. Chaiyakunapruk2

  • Abstract Number: PB0365

    Presentation of the Patient with Low Peak Dabigatran Levels in Plasma Suggests the Importance of Quantitative Measurement of DOAC Drugs in Clinical Decision Making and Treatment

    S. Margetić1, I. Ćelap1, A. Lovrenčić-Huzjan2, M. Bosnar Puretić2, M. Roje Bedeković2, M. Razum1, R. Mihić1, S. Šupraha Goreta3

  • Abstract Number: PB0913

    Prevailing c.2435delC and Other VWF Gene Defects in Russian Patients with von Willebrand Disease Type 3. Four New Pathogenic Variants Found

    D. Chernetskaya1, E. Likhacheva1, F. Perina2, O. Pshenichnikova1, V. Surin1, N. Zozulya1

  • Abstract Number: PB1213

    Prevalence and Incidence of Deep Vein Thrombosis in Medical Critically Ill Patients: A Prospective Analysis in a Single Tertiary Care Centre in Thailand

    S. Arunothai1, T. Panpikoon2, K. Boonyawat3, Y. Sutherasan4, P. Theerawit4

  • Abstract Number: PB0929

    Prevalence and Predictors of Iron Deficiency Anemia in Women with von Willebrand Disease: An NIS Study

    A. Amouzegar1, K. Jeong2, J.G. Yabes2, M.V. Ragni3

  • Abstract Number: PB0612

    Prevalence of Hematuria in Patients with Hemophilia A and B and its Association with Comorbidities: Experience from a Brazilian Center

    D. Bittencourt Siqueira1, M. D'Auria Jacomassi1, L. Bassolli1, C. Rothschild1, E. Okazaki1, V. Rocha1, P. Villaca1

  • Abstract Number: PB0387

    Prevalence of Hemolysis, Icterus and Lipemia in the Coagulation Laboratory: Database Analyses

    F. Mil1, B. Girard1, A. Carlo2, D. Guimbard1

  • Abstract Number: PB0498

    Prevalence of Hypertension in Hemophilia Patients: A Systematic Review

    A. Ter-Zakarian1, K. Al Banaa1, R. Barnes1, A. von Drygalski1,2

  • Abstract Number: PB0831

    Prevalence of Thrombotic Events and Risk Factors in Patients with Primary Immune Thrombocytopenia

    A. Doblas-Marquez1, F.-J. Lopez-Jaime1, S. Martin-Tellez1, I. Sanchez-Bazan1, M.-I. Muñoz-Perez1

  • Abstract Number: PB0811

    Prevalence of Venous Thrombembolic Events in the Czech Pediatric Population – Epidemiological Study

    T. Kuhn1,2

  • Abstract Number: LPB0010

    Prevalence of Venous Thromboembolism and Pulmonary Embolism among Patients Hospitalized with a COVID-19 Diagnosis in France

    A. Gabet1, C. Grave1, P. Tuppin2, J. Emmerich3, V. Olié1

  • Abstract Number: PB0281

    Prevalence, Clinical Profile and Bleeding Risk of Hospitalized COVID-19 Patients Receiving Anticoagulation: A Retrospective Cross-sectional Study

    C. Imperial1,1

  • Abstract Number: PB1093

    Prevalence, Treatment and Prognosis of Tumor Thrombi in Renal Cell Carcinoma

    F.H.J. Kaptein1, S.J.E. Braken1, E.M.E. du Chatinier1, M.C. Burgmans2, J.T. Buijs1, S.C. Cannegieter1,3, E.J. van Gennep4, R.C.M. Pelger4, E.L. van Persijn van Meerten2, H.H. Versteeg1, M.V. Huisman1, T. van der Hulle5, F.A. Klok1

  • Abstract Number: LB 01.1

    Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone

    S.D. Berkowitz1, R.M. Bauersachs2, M. Szarek1, M.R. Nehler1, E.S. Debus3, M.R. Patel4, S.S. Anand5, C.N. Hess1, E. Muehlhofer6, L.P. Haskell7, M.P. Bonaca1

  • Abstract Number: OC 47.1

    Prevention of Thrombocytopenia and Thrombosis in Heparin-induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT?

    A. Sarkar1, S. Khandelwal2, S.V Yarovoi3, G.M Arepally2, D.B Cines3, M. Poncz1,4, L. Rauova1,4

  • Abstract Number: PB0625

    Primary Prophiliaxis was Associated with a Lower Risk of Joint Damage in Colombian Men Patients with Hemophilia A

    G.A. Diaz Mosquera1, S. Sarmiento Doncel2, J.M. Cortes1, F.J. Meza1, J.E. Peña1, C. Agudelo Rico3, N. Ramirez Plazas1, C.A. Montaño Mejia1, I.A. Perdomo Amar2, A. Maza Villadiego1, A. Parrado Rey1

  • Abstract Number: LPB0045

    Principles of Care for Women and Girls with Inherited Bleeding Disorders

    K. van Galen1, M. Lavin2, N. Skouw-Rasmussen3, D. Noone3, D. Pollard4, K. Khair5, K. Gomez6, K. Fischer1, E. van Loon7, C. Bagot8, P. Elfvinge9, R. D’Oiron10, R. Kadir11

  • Abstract Number: PB0175

    Prior Use of Therapeutic Anticoagulation Does Not Protect against COVID-19 Related Clinical Outcomes in Hospitalized Patients: A Propensity Score-matched Cohort Study

    J. Spiegelenberg1, M. van Gelder1, M. Maas2, M. Hovens3, A. Esselink4, A. Kerckhoffs5, J. Hoogerwerf1, N. Janssen1, M. van Apeldoorn5, K. Veerman6, M. Blaauw1, R. Janssen4, R.J. Hassing3, T. Dofferhoff4, J. van de Maat1, K. Kramers1, J. Leentjens1

  • Abstract Number: PB1084

    Procedural Success of Left Atrial Appendage Occlusion Device in Patients with Chronic Kidney Disease: Meta-analysis of Real-world Data

    A. Singh1, S. Hussain2, B. Antony1

  • Abstract Number: PB0428

    Producing if Tenecteplase with High Activity

    D. Chashchinova1, V. Leonov2, X. Smolova2, D. Kudlay1

  • Abstract Number: PB0313

    Profiling of Inflammatory Biomarkers and Coagulation Factors in End-stage Renal Disease

    E. Bontekoe1, A. Grewal1, V. Bansal1, M. Ben Hadj Tahar1, D. Hoppensteadt1, J. Fareed1

  • Abstract Number: PB0236

    Prognostic Coagulation Parameters in COVID-19 Patients at the ICU

    S. van de Leur1, S. Spanjersberg1, E. ter Haar1

  • Abstract Number: OC 73.3

    Prognostic Impact of Acute Kidney Injury in Patients with Acute Pulmonary Embolism. Data from the RIETE Registry

    L. Bertoletti1,2,3,4, M. Murgier5,6, B. Bikdeli7,8,9, D. Jimenez10, J. Trujillo-Santos11, A. Merah1,12, C. de Ancos13, Á. Fidalgo14, J. Aibar15, M. Monreal16

  • Abstract Number: PB0012

    Prognostic Significance of von Willebrand Factor in Flow-mediated Dilatation Test at Patients with Arterial Hypertension and Diabetes Type 2

    E. Shorikov1, D. Shorikova1, P. Shorikov1

  • Abstract Number: OC 44.3

    Progression of Ischaemic and Haemorrhagic Brain Lesions on MRI in APS Patients on Antithrombotic Therapy

    M. Efthymiou1,2, P. SvrKova3,4,2, R. Moll1,2, S. Nallamilli1,2, A.R. Alexandre5,6, D. Isenberg6,2, D. Werring3,4,2, R.H Jager3,4,2, H. Cohen1,2

  • Abstract Number: PB0418

    Prolonged Tourniquet Application in the Hind Limb of Rats Is Associated with Fibrinolysis

    J. Chung1,2, O. Mian3,2, A.K. Chan4,2, D. Matino4,2

  • Abstract Number: PB0593

    Promising Prospective Data on the Effect of Ankle Joint Distraction in Hemophilic Arthropathy: Three Year Follow-up

    E. van Bergen1,1, L. van Vulpen1, H. Vogely1, P. de Kleijn1, W. Foppen1, P. van Roermund1, R. Schutgens1, S. Mastbergen1, F. Lafeber1

  • Abstract Number: PB0490

    Properties of FVIII Concentrate Were Obtained by the Method of Dye-ligand Affinity Chromatography

    N. Shurko1, T. Danysh1, V. Novak1

  • Abstract Number: PB0288

    Prophylactic Anticoagulation in Hospitalized Patients with COVID-19: A Survey of Practices in Latin America

    F. de Andrade Orsi1, P. Casais2, G. Cesarman-Maus3, C. Guillermo4, R. Martinez4, S. Rezende5

  • Abstract Number: PB1312

    Prophylactic Radiological Interventions to Reduce Postpartum Haemorrhage in Patients with Placenta Accreta Spectrum Disorders

    L. Bonsen1,2, V. Harskamp3, S. Feddouli1,3, J. Duvekot4, A. Pors3, K. Bloemenkamp5, J. van Roosmalen1,6, M. van Kraaij7, J. Zwart8, J. van Lith1, T. van den Akker1,9, D. Henriquez1,2,3, J. van der Bom2,3, TeMpOH-3 study group

  • Abstract Number: PB0919

    Prophylactic Subcutaneous Emicizumab-kxwh in Adults and Children with Symptomatic Type 3 von Willebrand Disease

    A. Pawar1, K. Braunstein2, J. Michals1, K. Vo1, K. Schafer1

  • Abstract Number: OC 51.1

    Prospective Cohort Study on the Use of Low Molecular Weight Heparin Calibrated Anti-Xa Assay to Estimate Levels of Direct Oral Xa Inhibitors in Ex-vivo Patient Samples

    M.S. Lim1, R. Hayes2, A. Sharma3, T. Kitipornchai2, M. Mohamed1, S. Mcrae1

  • Abstract Number: PB1210

    Prospective Cohort: A 10 Years Experience with Hospitalized Patients with Venous Thromboembolic Disease from a Single-center Institutional Registry, Argentina

    F.J. Vázquez1, M.F. Grande Ratti1, M.A. Burgos1, M.E. Zapiola1, D.H. Giunta1, M.L. Posadas-Martinez1

  • Abstract Number: PB0599

    Prospective, Non-interventional Study with a Cohort to Assess Real-world Effectiveness (RWE) and Safety of Emicizumab in Persons with Hemophilia A (PwHA) without Inhibitors in Spain, Hemolution Cohort

    M.T. Álvarez Román1, I. Soto2, H. de la Corte1, P. Bosh3, Á. Lavandeira4, C. Alvarez5, I. Guerra5

  • Abstract Number: PB0502

    Prospective, Open-label, Multicentre Phase II Study (PeKaFIX) to Evaluate the Pharmacokinetic Parameters of a Plasma Derived Factor IX Concentrate and Build a Pharmacokinetic Bayesian Model

    C. Negrier1, on behalf of the PekaFIX study Group

  • Abstract Number: PB0615

    Prostate Surgery in Patients with Hemophilia: A Monocentric Real-life Experience

    N. Drillaud1, B. Mesnard2, M. Sigaud1, M. Fouassier1, C. Ternisien1, M.-C. Bene3, J. Branchereau2, M. Trossaërt1

  • Abstract Number: OC 35.3

    Protein Arginine Deiminase 4 Inactivates Tissue Factor Pathway Inhibitor by Post-translational Modification of Functional Arginine Residues

    M.C.L. Thomassen1, B.R. Bouwens1, K. Wichapong1, D.P. Suylen1, F.G. Bouwman2, T.M. Hackeng1, R.R Koenen1

  • Abstract Number: OC 35.2

    Protein S Coordinates the Synergistic Inhibition of Prothrombinase by Tfpiα and Activated Protein C

    X. Li1, X. Song1, M.M. Sim1, J.P. Wood1

  • Abstract Number: PB0395

    Protein S Gla Domain as Theranostic for Early Vascular Calcification

    A. Gentier1, S. Agten1, L. Schurgers1, T. Hackeng1

  • Abstract Number: PB0315

    Proteome Analysis of Extracellular Vesicles from Patients with Myocardial Infarction and Relation to Heart Function: An Observational Study

    A. Khandagale1, S. Bergström Lind2, G. Shevchenko2, J. Westerbergh3, B. Lindahl1,3, A. Siegbahn4, C. Christersson1

  • Abstract Number: LPB0044

    Prothrombotic Biomarkers during Controlled Ovarian Stimulation for Assisted Reproductive Techniques

    J. Hugon-Rodin1, A. Casini2, J. Bénard2, A. Poncet2, P. Fontana2, N. Vulliemoz3, I. Streuli2

  • Abstract Number: PB0988

    Prototyping of Physiological Stenosis with 2-photon Lithography for Thrombosis Studies

    Y.J. Lim1,2, Y. Li2, E.E. Gardiner1, W.M. Lee1,2

  • Abstract Number: PB0760

    PSGL-1 is Important for Platelet-monocyte Aggregate Formation and Monocyte Maturation in Lentiviral Infection

    C. Lyons1,2, E. Shirk1, S. Vijay1, A. Feng1, M.R. Richardson1, Z. Gholizadeh1, B. Carlson1, S. Guerrero-Martin1,2, K. Metcalf Pate1,2

  • Abstract Number: OC 34.1

    Pulmonary Embolism and Deep Vein Thrombosis – Incidence, Comorbidities and Temporary Provoking Factors – A Nationwide Registry Study of 298,172 Patients

    K. Glise Sandblad1, S. Jern2, J. Sörbo3, A. Rosengren1, P.-O. Hansson1

  • Abstract Number: PB1178

    Pulmonary Embolism Diagnosis: Let’s Practice what we Preach. A Quality Improvement Study to Increase Adherence to Evidence-based PE Diagnosis in the Emergency Department

    F. Germini1, F. Al-haimus1, Y. Hu1, S. Niaz1, N. Clayton1, S. Mondoux1, Q. Ibrahim1, L. Thabane1, K. de Wit1

  • Abstract Number: PB0265

    Pulmonary Embolism in COVID-19-Patients: Diagnostic Accuracy of D-dimer

    F. Laouan Brem1, C. Miri1, H. Rasras1, A. Boudouh2, Y. Amane3, M.-A. Bouazzaoui4, S. Nasri3, I. Skiker3, N. Abda4, H. Kouismi2, Z. Bazid1, N. Ismaili1,4, N. El Ouafi1,4

  • Abstract Number: PB1146

    Pulmonary Embolism in the Onset of Hematogenous Thrombophilia

    V. Voitsekhovsky1, T. Zabolotskikh1, I. Sayapina1, O. Prikhodko1, T. Luchnikova1, E. Romantsova1, N. Grigoriev1

  • Abstract Number: PB0176

    Pulmonary Thromboembolism (PTE) in Hospitalised Patients with COVID-19: A National Study of Patients Managed in Critical Care and Ward Environments

    M. McGettrick1, A. MacLellan1, P. McCaughey1, C. Bagot2, M. Brewis1, N.N Lang3, M. Johnson1, A.C. Church1

  • Abstract Number: OC 55.2

    Purifying the Needle in the Haystack: A Novel Immunoproteomic Pipeline for the Characterization Anti-FVIII Antibodies in Hemophilia A Inhibitor Patients

    R. Chen1, B. Doshi2,3, S. Lopez4, X. Pan4, A.S. Fahad4, M.F. Gutierrez Gonzalez4, B. Dekosky4, V. Arruda3,2, V. Bhoj1, B. Samelson-Jones3,2

Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley